Category name (PANTHER pathway accession number) | Number of gene hits | Percent of gene hit against total number of genes | Percent of gene hit against total number of pathway hits |
---|---|---|---|
2-arachidonoylglycerol biosynthesis (P05726) | 4 | 0.00Â % | 0.10Â % |
5-Hydroxytryptamine biosynthesis (P04371) | 2 | 0.00Â % | 0.00Â % |
5-Hydroxytryptamine degradation (P04372) | 3 | 0.00Â % | 0.10Â % |
5HT1 type receptor mediated signaling pathway (P04373) | 25 | 0.20Â % | 0.60Â % |
5HT2 type receptor mediated signaling pathway (P04374) | 39 | 0.30Â % | 1.00Â % |
5HT3 type receptor mediated signaling pathway (P04375) | 12 | 0.10Â % | 0.30Â % |
5HT4 type receptor mediated signaling pathway (P04376) | 16 | 0.10Â % | 0.40Â % |
Acetate utilization (P02722) | 3 | 0.00Â % | 0.10Â % |
Activin-beta signaling pathway (P06210) | 3 | 0.00Â % | 0.10Â % |
Adenine and hypoxanthine salvage pathway (P02723) | 6 | 0.10Â % | 0.10Â % |
Adrenaline and noradrenaline biosynthesis (P00001) | 22 | 0.20Â % | 0.50Â % |
Alanine biosynthesis (P02724) | 2 | 0.00Â % | 0.00Â % |
ALP23B_signaling_pathway (P06209) | 3 | 0.00Â % | 0.10Â % |
Alpha adrenergic receptor signaling pathway (P00002) | 20 | 0.20Â % | 0.50Â % |
Alzheimer disease-amyloid secretase pathway (P00003) | 50 | 0.40Â % | 1.20Â % |
Alzheimer disease-presenilin pathway (P00004) | 74 | 0.60Â % | 1.80Â % |
Aminobutyrate degradation (P02726) | 2 | 0.00Â % | 0.00Â % |
Androgen/estrogene/progesterone biosynthesis (P02727) | 3 | 0.00Â % | 0.10Â % |
Angiogenesis (P00005) | 125 | 1.10Â % | 3.10Â % |
Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911) | 30 | 0.30Â % | 0.70Â % |
Apoptosis signaling pathway (P00006) | 80 | 0.70Â % | 2.00Â % |
Arginine biosynthesis (P02728) | 4 | 0.00Â % | 0.10Â % |
Ascorbate degradation (P02729) | 2 | 0.00Â % | 0.00Â % |
Asparagine and aspartate biosynthesis (P02730) | 4 | 0.00Â % | 0.10Â % |
ATP synthesis (P02721) | 6 | 0.10Â % | 0.10Â % |
Axon guidance mediated by netrin (P00009) | 29 | 0.30Â % | 0.70Â % |
Axon guidance mediated by semaphorins (P00007) | 18 | 0.20Â % | 0.40Â % |
Axon guidance mediated by Slit/Robo (P00008) | 18 | 0.20Â % | 0.40Â % |
B cell activation (P00010) | 49 | 0.40Â % | 1.20Â % |
Beta1 adrenergic receptor signaling pathway (P04377) | 26 | 0.20Â % | 0.60Â % |
Beta2 adrenergic receptor signaling pathway (P04378) | 26 | 0.20Â % | 0.60Â % |
Beta3 adrenergic receptor signaling pathway (P04379) | 11 | 0.10Â % | 0.30Â % |
Blood coagulation (P00011) | 22 | 0.20Â % | 0.50Â % |
BMP_signaling_pathway-drosophila (P06211) | 2 | 0.00Â % | 0.00Â % |
Cadherin signaling pathway (P00012) | 103 | 0.90Â % | 2.50Â % |
Carnitine and CoA metabolism (P02732) | 1 | 0.00Â % | 0.00Â % |
Carnitine metabolism (P02733) | 1 | 0.00Â % | 0.00Â % |
Cell cycle (P00013) | 17 | 0.10Â % | 0.40Â % |
Cholesterol biosynthesis (P00014) | 9 | 0.10Â % | 0.20Â % |
Circadian clock system (P00015) | 9 | 0.10Â % | 0.20Â % |
Coenzyme A biosynthesis (P02736) | 6 | 0.10Â % | 0.10Â % |
Cortocotropin releasing factor receptor signaling pathway (P04380) | 27 | 0.20Â % | 0.70Â % |
Cysteine biosynthesis (P02737) | 1 | 0.00Â % | 0.00Â % |
Cytoskeletal regulation by Rho GTPase (P00016) | 57 | 0.50Â % | 1.40Â % |
De novo purine biosynthesis (P02738) | 19 | 0.20Â % | 0.50Â % |
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739) | 6 | 0.10Â % | 0.10Â % |
De novo pyrmidine ribonucleotides biosythesis (P02740) | 8 | 0.10Â % | 0.20Â % |
DNA replication (P00017) | 19 | 0.20Â % | 0.50Â % |
Dopamine receptor mediated signaling pathway (P05912) | 48 | 0.40Â % | 1.20Â % |
DPP_signaling_pathway (P06213) | 2 | 0.00Â % | 0.00Â % |
DPP-SCW_signaling_pathway (P06212) | 2 | 0.00Â % | 0.00Â % |
EGF receptor signaling pathway (P00018) | 101 | 0.90Â % | 2.50Â % |
Endogenous_cannabinoid_signaling (P05730) | 18 | 0.20Â % | 0.40Â % |
Endothelin signaling pathway (P00019) | 65 | 0.60Â % | 1.60Â % |
Enkephalin release (P05913) | 17 | 0.10Â % | 0.40Â % |
FAS signaling pathway (P00020) | 24 | 0.20Â % | 0.60Â % |
FGF signaling pathway (P00021) | 86 | 0.70Â % | 2.10Â % |
Flavin biosynthesis (P02741) | 2 | 0.00Â % | 0.00Â % |
Folate biosynthesis (P02742) | 2 | 0.00Â % | 0.00Â % |
Formyltetrahydroformate biosynthesis (P02743) | 4 | 0.00Â % | 0.10Â % |
Fructose galactose metabolism (P02744) | 9 | 0.10Â % | 0.20Â % |
GABA-B_receptor_II_signaling (P05731) | 30 | 0.30Â % | 0.70Â % |
Gamma-aminobutyric acid synthesis (P04384) | 5 | 0.00Â % | 0.10Â % |
GBB_signaling_pathway (P06214) | 2 | 0.00Â % | 0.00Â % |
General transcription by RNA polymerase I (P00022) | 13 | 0.10Â % | 0.30Â % |
General transcription regulation (P00023) | 30 | 0.30Â % | 0.70Â % |
Glutamine glutamate conversion (P02745) | 2 | 0.00Â % | 0.00Â % |
Glycolysis (P00024) | 18 | 0.20Â % | 0.40Â % |
Gonadotropin releasing hormone receptor pathway (P06664) | 185 | 1.60Â % | 4.60Â % |
Hedgehog signaling pathway (P00025) | 19 | 0.20Â % | 0.50Â % |
Heme biosynthesis (P02746) | 8 | 0.10Â % | 0.20Â % |
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026) | 103 | 0.90Â % | 2.50Â % |
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P00027) | 86 | 0.70Â % | 2.10Â % |
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction (P00028) | 17 | 0.10Â % | 0.40Â % |
Histamine H1 receptor mediated signaling pathway (P04385) | 22 | 0.20Â % | 0.50Â % |
Histamine H2 receptor mediated signaling pathway (P04386) | 9 | 0.10Â % | 0.20Â % |
Huntington disease (P00029) | 112 | 1.00Â % | 2.80Â % |
Hypoxia response via HIF activation (P00030) | 21 | 0.20Â % | 0.50Â % |
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 135 | 1.20Â % | 3.30Â % |
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032) | 26 | 0.20Â % | 0.60Â % |
Insulin/IGF pathway-protein kinase B signaling cascade (P00033) | 30 | 0.30Â % | 0.70Â % |
Integrin signalling pathway (P00034) | 135 | 1.20Â % | 3.30Â % |
Interferon-gamma signaling pathway (P00035) | 24 | 0.20Â % | 0.60Â % |
Interleukin signaling pathway (P00036) | 59 | 0.50Â % | 1.50Â % |
Ionotropic glutamate receptor pathway (P00037) | 41 | 0.40Â % | 1.00Â % |
Isoleucine biosynthesis (P02748) | 3 | 0.00Â % | 0.10Â % |
JAK/STAT signaling pathway (P00038) | 15 | 0.10Â % | 0.40Â % |
Leucine biosynthesis (P02749) | 2 | 0.00Â % | 0.00Â % |
Lipoate_biosynthesis (P02750) | 2 | 0.00Â % | 0.00Â % |
Mannose metabolism (P02752) | 5 | 0.00Â % | 0.10Â % |
Metabotropic glutamate receptor group I pathway (P00041) | 19 | 0.20Â % | 0.50Â % |
Metabotropic glutamate receptor group II pathway (P00040) | 25 | 0.20Â % | 0.60Â % |
Metabotropic glutamate receptor group III pathway (P00039) | 45 | 0.40Â % | 1.10Â % |
Methionine biosynthesis (P02753) | 2 | 0.00Â % | 0.00Â % |
Methylcitrate cycle (P02754) | 2 | 0.00Â % | 0.00Â % |
Methylmalonyl pathway (P02755) | 3 | 0.00Â % | 0.10Â % |
mRNA splicing (P00058) | 6 | 0.10Â % | 0.10Â % |
Muscarinic acetylcholine receptor 1 and 3 signaling pathway (P00042) | 38 | 0.30Â % | 0.90Â % |
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (P00043) | 29 | 0.30Â % | 0.70Â % |
P53 pathway feedback loops 1 (P04392) | 5 | 0.00Â % | 0.10Â % |
P53Â pathway feedback loops 2 (P04398) | 41 | 0.40Â % | 1.00Â % |
Parkinson disease (P00049) | 74 | 0.60Â % | 1.80Â % |
PDGF signaling pathway (P00047) | 105 | 0.90Â % | 2.60Â % |
Pentose phosphate pathway (P02762) | 7 | 0.10Â % | 0.20Â % |
Phenylethylamine degradation (P02766) | 1 | 0.00Â % | 0.00Â % |
PI3 kinase pathway (P00048) | 40 | 0.30Â % | 1.00Â % |
Plasminogen activating cascade (P00050) | 3 | 0.00Â % | 0.10Â % |
PLP biosynthesis (P02759) | 1 | 0.00Â % | 0.00Â % |
Proline biosynthesis (P02768) | 4 | 0.00Â % | 0.10Â % |
Purine metabolism (P02769) | 7 | 0.10Â % | 0.20Â % |
Pyridoxal phosphate salvage pathway (P02770) | 1 | 0.00Â % | 0.00Â % |
Pyrimidine Metabolism (P02771) | 8 | 0.10Â % | 0.20Â % |
Pyruvate metabolism (P02772) | 6 | 0.10Â % | 0.10Â % |
Ras Pathway (P04393) | 61 | 0.50Â % | 1.50Â % |
S adenosyl methionine biosynthesis (P02773) | 2 | 0.00Â % | 0.00Â % |
Salvage pyrimidine deoxyribonucleotides (P02774) | 1 | 0.00Â % | 0.00Â % |
Salvage pyrimidine ribonucleotides (P02775) | 6 | 0.10Â % | 0.10Â % |
SCW_signaling_pathway (P06216) | 2 | 0.00Â % | 0.00Â % |
Serine glycine biosynthesis (P02776) | 5 | 0.00Â % | 0.10Â % |
Succinate to proprionate conversion (P02777) | 2 | 0.00Â % | 0.00Â % |
Sulfate assimilation (P02778) | 2 | 0.00Â % | 0.00Â % |
Synaptic_vesicle_trafficking (P05734) | 24 | 0.20Â % | 0.60Â % |
T cell activation (P00053) | 58 | 0.50Â % | 1.40Â % |
TCA cycle (P00051) | 9 | 0.10Â % | 0.20Â % |
TGF-beta signaling pathway (P00052) | 62 | 0.50Â % | 1.50Â % |
Thiamine metabolism (P02780) | 3 | 0.00Â % | 0.10Â % |
Threonine biosynthesis (P02781) | 2 | 0.00Â % | 0.00Â % |
Thyrotropin-releasing hormone receptor signaling pathway (P04394) | 35 | 0.30Â % | 0.90Â % |
Toll receptor signaling pathway (P00054) | 39 | 0.30Â % | 1.00Â % |
Toll_pathway_drosophila (P06217) | 1 | 0.00Â % | 0.00Â % |
Transcription regulation by bZIP transcription factor (P00055) | 41 | 0.40Â % | 1.00Â % |
Triacylglycerol metabolism (P02782) | 1 | 0.00Â % | 0.00Â % |
Tryptophan biosynthesis (P02783) | 1 | 0.00Â % | 0.00Â % |
Tyrosine biosynthesis (P02784) | 1 | 0.00Â % | 0.00Â % |
Ubiquitin proteasome pathway (P00060) | 50 | 0.40Â % | 1.20Â % |
Valine biosynthesis (P02785) | 3 | 0.00Â % | 0.10Â % |
Vasopressin synthesis (P04395) | 11 | 0.10Â % | 0.30Â % |
VEGF signaling pathway (P00056) | 47 | 0.40Â % | 1.20Â % |
Vitamin B6 metabolism (P02787) | 3 | 0.00Â % | 0.10Â % |
Vitamin D metabolism and pathway (P04396) | 7 | 0.10Â % | 0.20Â % |
Wnt signaling pathway (P00057) | 211 | 1.80Â % | 5.20Â % |
Xanthine and guanine salvage pathway (P02788) | 4 | 0.00Â % | 0.10Â % |